A Randomized, Placebo-controlled, Double-blind Trial of Multiple Ascending Doses of ZP4207 Administered to Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP4207
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2015
At a glance
- Drugs Dasiglucagon (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions
- Sponsors Zealand Pharma
- 26 Jun 2015 According to a Zealand Pharma media release, results of this study are expected in H2 2015.
- 26 Jun 2015 Status changed from recruiting to completed, according to a Zealand Pharma media release.
- 20 May 2015 Results are expected in the second half of 2015, according to a Zealand Pharma media release.